These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 15504964)

  • 1. Pioglitazone reduces islet triglyceride content and restores impaired glucose-stimulated insulin secretion in heterozygous peroxisome proliferator-activated receptor-gamma-deficient mice on a high-fat diet.
    Matsui J; Terauchi Y; Kubota N; Takamoto I; Eto K; Yamashita T; Komeda K; Yamauchi T; Kamon J; Kita S; Noda M; Kadowaki T
    Diabetes; 2004 Nov; 53(11):2844-54. PubMed ID: 15504964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PPAR-γ activation restores pancreatic islet SERCA2 levels and prevents β-cell dysfunction under conditions of hyperglycemic and cytokine stress.
    Kono T; Ahn G; Moss DR; Gann L; Zarain-Herzberg A; Nishiki Y; Fueger PT; Ogihara T; Evans-Molina C
    Mol Endocrinol; 2012 Feb; 26(2):257-71. PubMed ID: 22240811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion.
    Lupi R; Del Guerra S; Marselli L; Bugliani M; Boggi U; Mosca F; Marchetti P; Del Prato S
    Am J Physiol Endocrinol Metab; 2004 Apr; 286(4):E560-7. PubMed ID: 14625208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pioglitazone improves insulin secretory capacity and prevents the loss of beta-cell mass in obese diabetic db/db mice: Possible protection of beta cells from oxidative stress.
    Ishida H; Takizawa M; Ozawa S; Nakamichi Y; Yamaguchi S; Katsuta H; Tanaka T; Maruyama M; Katahira H; Yoshimoto K; Itagaki E; Nagamatsu S
    Metabolism; 2004 Apr; 53(4):488-94. PubMed ID: 15045697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic steatosis with relation to increased expression of peroxisome proliferator-activated receptor-γ in insulin resistant mice.
    Satoh H; Ide N; Kagawa Y; Maeda T
    Biol Pharm Bull; 2013; 36(4):616-23. PubMed ID: 23386130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination peroxisome proliferator-activated receptor gamma and alpha agonist treatment in Type 2 diabetes prevents the beneficial pioglitazone effect on liver fat content.
    Balasubramanian R; Gerrard J; Dalla Man C; Firbank MJ; Lane A; English PT; Cobelli C; Taylor R
    Diabet Med; 2010 Feb; 27(2):150-6. PubMed ID: 20546257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy with PPARgamma and PPARalpha agonists increases glucose-stimulated insulin secretion in db/db mice.
    Yajima K; Hirose H; Fujita H; Seto Y; Fujita H; Ukeda K; Miyashita K; Kawai T; Yamamoto Y; Ogawa T; Yamada T; Saruta T
    Am J Physiol Endocrinol Metab; 2003 May; 284(5):E966-71. PubMed ID: 12676649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural and functional analysis of pancreatic islets preserved by pioglitazone in db/db mice.
    Kawasaki F; Matsuda M; Kanda Y; Inoue H; Kaku K
    Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E510-8. PubMed ID: 15522998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterozygous deletion of Seipin in islet beta cells of male mice has an impact on insulin synthesis and secretion through reduced PPARγ expression.
    Xiong J; Sun P; Wang Y; Hua X; Song W; Wang Y; Wu J; Yu W; Liu G; Chen L
    Diabetologia; 2020 Feb; 63(2):338-350. PubMed ID: 31776610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of peroxisome proliferator-activated receptor-gamma by rosiglitazone protects human islet cells against human islet amyloid polypeptide toxicity by a phosphatidylinositol 3'-kinase-dependent pathway.
    Lin CY; Gurlo T; Haataja L; Hsueh WA; Butler PC
    J Clin Endocrinol Metab; 2005 Dec; 90(12):6678-86. PubMed ID: 16204373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PPAR-gamma overexpression suppresses glucose-induced proinsulin biosynthesis and insulin release synergistically with pioglitazone in MIN6 cells.
    Nakamichi Y; Kikuta T; Ito E; Ohara-Imaizumi M; Nishiwaki C; Ishida H; Nagamatsu S
    Biochem Biophys Res Commun; 2003 Jul; 306(4):832-6. PubMed ID: 12821117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and beagle dogs.
    Kasai S; Inoue T; Yoshitomi H; Hihara T; Matsuura F; Harada H; Shinoda M; Tanaka I
    J Pharmacol Sci; 2008 Sep; 108(1):40-8. PubMed ID: 18776709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of increased PPARgamma activity in adipocytes in vivo on adiposity, insulin sensitivity and the effects of rosiglitazone treatment.
    Takasawa K; Kubota N; Terauchi Y; Kadowaki T
    Endocr J; 2008 Aug; 55(4):767-76. PubMed ID: 18506083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of PPARγ specifically in pancreatic β-cells exacerbates obesity-induced glucose intolerance, reduces β-cell mass, and alters islet lipid metabolism in male mice.
    Hogh KL; Craig MN; Uy CE; Nygren H; Asadi A; Speck M; Fraser JD; Rudecki AP; Baker RK; Orešič M; Gray SL
    Endocrinology; 2014 Oct; 155(10):3843-52. PubMed ID: 25051434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kaempferia parviflora Ethanol Extract, a Peroxisome Proliferator-Activated Receptor γ Ligand-binding Agonist, Improves Glucose Tolerance and Suppresses Fat Accumulation in Diabetic NSY Mice.
    Ochiai M; Takeuchi T; Nozaki T; Ishihara KO; Matsuo T
    J Food Sci; 2019 Feb; 84(2):339-348. PubMed ID: 30726580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pioglitazone attenuates fatty acid-induced oxidative stress and apoptosis in pancreatic beta-cells.
    Saitoh Y; Chun-ping C; Noma K; Ueno H; Mizuta M; Nakazato M
    Diabetes Obes Metab; 2008 Jul; 10(7):564-73. PubMed ID: 17593232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroxisome proliferator-activated receptor alpha (PPARalpha) potentiates, whereas PPARgamma attenuates, glucose-stimulated insulin secretion in pancreatic beta-cells.
    Ravnskjaer K; Boergesen M; Rubi B; Larsen JK; Nielsen T; Fridriksson J; Maechler P; Mandrup S
    Endocrinology; 2005 Aug; 146(8):3266-76. PubMed ID: 15878969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones.
    Hevener AL; Olefsky JM; Reichart D; Nguyen MT; Bandyopadyhay G; Leung HY; Watt MJ; Benner C; Febbraio MA; Nguyen AK; Folian B; Subramaniam S; Gonzalez FJ; Glass CK; Ricote M
    J Clin Invest; 2007 Jun; 117(6):1658-69. PubMed ID: 17525798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peroxisome proliferator-activated receptor alpha improves pancreatic adaptation to insulin resistance in obese mice and reduces lipotoxicity in human islets.
    Lalloyer F; Vandewalle B; Percevault F; Torpier G; Kerr-Conte J; Oosterveer M; Paumelle R; Fruchart JC; Kuipers F; Pattou F; Fiévet C; Staels B
    Diabetes; 2006 Jun; 55(6):1605-13. PubMed ID: 16731822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pioglitazone can ameliorate insulin resistance in low-dose streptozotocin and high sucrose-fat diet induced obese rats.
    Ding SY; Shen ZF; Chen YT; Sun SJ; Liu Q; Xie MZ
    Acta Pharmacol Sin; 2005 May; 26(5):575-80. PubMed ID: 15842776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.